ArticleAIDS (London, England)2026
Sustained viral suppression among people with HIV in the era of Undetectable = Untransmittable (U = U) in Australia.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn Australia, cross-sectional estimates suggest that over 95% of people with HIV are virally suppressed; however, these measures reflect only the most recent viral load. Sustained viral suppression (SVS) is essential for optimizing health and preventing transmission. This study describes SVS among people with HIV who are engaged in care in Australia and factors associated with SVS.
methodsWe analyzed national data from the ACCESS sentinel surveillance system. Eligible participants attended an ACCESS clinic in 2023, received continuous antiretroviral therapy (ART; ≥1 prescription per calendar year), and had at least two viral load tests in the preceding three years (median:6; IQR: 5-7). SVS was defined as all viral load results less than 200 copies/ml. Multivariable logistic regression identified factors associated with SVS.
resultsOf 6036 eligible participants (95% men; median age 54 years), 5751 (95.3%) achieved SVS, while 99.1% were suppressed based on their last test. Older age (adjusted odds ratio [aOR]: 1.01; 95% confidence interval (95% CI): 1.002-1.03), residence in more socioeconomically advantaged areas (aOR: 1.06; 1.01-1.12), and higher mean CD4 + cell count (aOR: 1.00; 1.001-1.002) were associated with higher odds of SVS. Receiving care at publicly funded sexual health/hospital-based clinics (aOR:0.64; 0.48-0.86), more diagnoses of gonorrhea (aOR: 0.81; 0.67-0.96) or infectious syphilis in the last three years (aOR: 0.85; 0.73-0.98), and co-infection with hepatitis C in the last 3 years (aOR: 0.56; 0.36-0.87) were associated with lower SVS.
conclusionsMore than 95% of people with HIV receiving ART and engaged in ongoing care achieved SVS. Strengthened, person-centered support for groups with lower SVS may enhance clinical outcomes and sustain Australia's progress toward HIV elimination goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.